Therapy of human transitioneal cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide

Clinical Cancer Research

Volumn 3, Issue 2, 1997, Pages 161-168

  Dinney, Colin P N ^a   Parker, Craig ^a   Dong, Zhongyun ^a   Fan, Dominic ^a   Eve, Beryl Y ^a   Bucana, Corazon ^a   Radinsky, Robert ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; 4,5 DIANILINOPHTHALIMIDE; 4,5 DIANILINOPHTHALIMIDE DERIVATIVE; CGP 54211; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; 4,5-DIANILINOPHTHALIMIDE; ADENOSINE TRIPHOSPHATE; PHTHALIMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHTHALIMIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0030608636     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Carpenter, G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem., 56: 881-914, 1987.
2. Yarden, Y., and Ullrich, A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem., 57: 443-478, 1988.
3. Messing, E. M. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Semin. Surg. Oncol., 8: 285-292, 1992.
4. Ahas, I., Mendelsohn, J., Baserga, J., Fair, W. R., Masur, H., and Kumar, R. Growth regulation of human renal carcinoma cells: role of transforming growth factor a. Cancer Res., 52: 3335-3339, 1992.
5. Carpenter, C. D., Ingraham, H. A., Cochet, C. Walton, G. M., Lazar, C. S., Sowadski, J. M., Rosenfeld, M. G., and Gill, G. N. Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J. Biol. Chem., 266: 5750-5755, 1991.
6. Neal, D. E., Sharples, L., Smith, K., Fennelly, J., Hall, R. R., and Harris, A. L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (Phila.), 65: 1619-1625, 1990.
7. Ullrich, A., and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61: 203-212, 1990.
8. Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755-7760, 1984.
9. Sunada, H., Yu, P., Peacock, J. S., and Mendelsohn, J. Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J. Cell. Physiol., 142: 284-292, 1990.
10. Cardinali, M., Sartor, O., and Robbins, K. C. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J. Clin. Invest., 89: 1242-1247, 1992.
11. Piontec, M., Hengels, K-J., Porschen, R., and Strohmeyer, G. Antiproliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells. Anticancer Res., 13: 2119-2124, 1993.
12. Fotsis, T., Pepper, M., Adlercreutz, H., Fleischmann, G., Hase, T., Montesano, R., and Schweigerer, L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA, 90: 2690-2694, 1993.
13. Friedman, B. A., Fujiki, H., and Rosner, M. R. Regulation of the epidermal growth factor receptor by growth-modulating agents: effects of staurosporine, a protein kinase inhibitor. Cancer Res., 50: 533-538, 1990.
14. Bruke, T. R. Protein tyrosine kinase inhibitors. Drugs Future, 17: 119-131, 1992.
15. Trinks, U., Buchdunger, E., Furet, P., Kump, W., Mett, H., Meyer, T., Muller, M., Regenass, U., Rihs, G., Lydon, N., and Traxler, P. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem., 37: 1015-1027, 1994.
16. Buchdunger, E., Trinks, U., Mett, H., Regenass, U., Muller, M., Meyer, T., McGlynn, E., Pinna, L. A., Traxler, P., and Lydon, N. B. 4,5-Dianilinophthalimide: a protein tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA, 91: 2334-2338, 1994.
17. Radinsky, R., Risin, S., Fan, D., Dong, Z., Bielenberg, D., Bucana, C. D., and Fidler, I. J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res., 1: 19-31, 1995.
18. Dinney, C. P. N., Fishbeck, R., Singh, R. K., Eve, B., Pathak, S., Brown, N., Xie, B., Fan, D., Bucana, C. D., Fidler, I. J., and Killion, J. J. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J. Urol., 154: 1532-1538, 1995.
19. Sorkin, A., Helin, K., Waters, C. M., Carpenter, G., and Beguinot, L. Multiple autophosphorylation sites of the epidermal growth factor receptor are essential for receptor kinase activity and internalization: contrasting significance of tyrosine 992 in the native and truncated receptors. J. Biol. Chem., 267: 8672-8678, 1992.
20. Campos-Gonzalez, R., and Glenney, J. R., Jr. Immunodetection of the ligand-activated receptor for epidermal growth factor. Growth Factors, 4: 305-316, 1991.
21. Siegall, C. B., FitzGerald, D. J., and Pastan, I. Selective killing of tumor cells using EGF or TGFα-Pseudomonas exotoxin chimeric molecules. Semin. Cancer Biol., 1: 345-350, 1990.
22. Sarosdy, M. F., Hutzier, D. H., Yee, D., and Von Hoff, D. D. In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. J. Urol., 150: 1950-1955, 1993.
23. Goldberg, M. R., Heimbrook, D. C., Russo, P., Sarosdy, M. F., Greenberg, R. E., Giantonio, B. J., Linehan, W. M., Walther, M., Fisher, H. A. G., Messing, E., Crawford, E. D., Oliff, A. I., and Pastan, I. H. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res., 1: 57-61, 1995.
24. Fry, D. W., Kraker, A. J., McMichael, A., Ambrose, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
25. Duello, T. M., Bertics, P. J., Fulgham, D. L., and Van Ess, P. J. Localization of epidermal growth factor receptors in first- and third-trimester human placentas. J. Histochem. Cytochem., 42: 907-915, 1994.